Krsnaa Diagnostics Limited has informed the Exchange regarding a press release dated May 12, 2025, titled "Press Release".
KRSNAA · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Krsnaa Diagnostics reported strong FY25 results with revenue rising 16% year-on-year to ₹717 crore, driven by higher patient volumes and competitive pricing across its diagnostic network. Profit after tax (PAT) surged 37% to ₹78 crore, the highest growth since listing, while EBITDA grew 34% to ₹196 crore with margins expanding to 27% from 24% the previous year. EPS jumped 36% to ₹23.56, and the board recommended a 55% dividend. The company is transitioning to an asset-light model through partnerships with Medikabazaar and United Imaging for over 30 imaging machines on deferred payment, and is expanding into PET-CT oncology services via investment in Apulki Healthcare. Management highlighted a 75% tender win ratio across PPP contracts in 12 states for pathology and 19 states for radiology.
Strong across-the-board growth in revenue, profitability, and margins signals robust operational momentum that is likely to be viewed positively by the market. The asset-light pivot and PPP tender wins support the case for sustained growth and improved return ratios going forward.